The Week in Review: December 15 – December 22, 2017

Friday, December 22, 2017 News Recap: Eight Genotypes: Did you know that there are now 8 genotypes and 84 subtypes of HCV that have been identified?  On the one hand this is terrible news; but on the other, a study presented at AASLD 2017 found that Vosevi was effective against them all.  Eight Genotypes and 84 Subtypes of HCV. Telemedicine: Did you know that Project ECHO (Extension for Community Health Outcomes), a fast-growing international tele...

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Direct-acting Antivirals Effective in Older Patients with Hepatitis C

Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials. "Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote. Satapathy